AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Fed’s Hammack Says Bond Yield Surge Is Not Driven by Inflation Fears 
Judge Blocks Trump Rule Limiting Foreign Student Visas 
Colombia Extradites FARC Dissident Leader ‘Spider’ to US 
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
Tesla Semi Rollout Begins at Nevada Factory 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
Airbus Finds A321neo Fuselage Quality Issue 
Evan Gershkovich Says FSB Set Trap for 2023 Russia Arrest 
Asian Currencies Mixed as Dollar Holds Near Two-Month High 
Add as a preferred source on Google
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
